Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Detalimogene voraplasmid - enGene

Next Previous
Drug Profile

Detalimogene voraplasmid - enGene

Alternative Names: Bladder cancer gene therapy - enGene; DDX® intravesicle gene therapy - enGene; Detalimogene; EG-70

Latest Information Update: 20 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator enGene
  • Class Antineoplastics; Gene therapies; Immunotherapies
  • Mechanism of Action DDX58 protein inhibitors; Gene transference; Interleukin 12 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Bladder cancer
  • Research Urogenital cancer

Most Recent Events

  • 20 Jan 2026 EnGene plans to file BLA for Bladder cancer to the US FDA in the second half of 2026
  • 20 Jan 2026 enGene expects potential commercial launch of detalimogene voraplasmid in Bladder cancer, in 2027
  • 22 Dec 2025 Efficacy and adverse events data from the phase I/II LENGEND trial in Bladder cancer released by enGene

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top